Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Enzalutamide and abiraterone have been shown to improve progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, some patients may not benefit from the inhibition of androgen receptor (AR) activity or, alternatively, may...

Full description

Bibliographic Details
Main Authors: Pierangela Sepe, Elena Verzoni, Patrizia Miodini, Melanie Claps, Raffaele Ratta, Antonia Martinetti, Roberta Mennitto, Elisa Sottotetti, Giuseppe Procopio, Vera Cappelletti, Maria Grazia Daidone
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
castration-resistant prostate cancer
abiraterone
enzalutamide
androgen receptor splicing variants
circulating tumor cells
liquid biopsy
precision medicine
Online Access:https://www.mdpi.com/2072-6694/11/7/980

Internet

https://www.mdpi.com/2072-6694/11/7/980

Similar Items